Product image of Mimpara (Cinacalcet) supplied by GNH India

Mimpara

Active Ingredient:
Cinacalcet
Origin:
EU

Mimpara (Cinacalcet)

Cinacalcet, the active ingredient in Mimpara, is a calcimimetic presented as an oral formulation for oral use. It is employed to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and to treat hypercalcemia associated with parathyroid carcinoma.

GNH India supplies Mimpara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mimpara (cinacalcet) acts on the calcium‑sensing pathway to control parathyroid hormone activity.

  • Secondary hyperparathyroidism in dialysis patients: reduces parathyroid hormone secretion, helping to lower serum calcium and phosphate levels.
  • Hypercalcemia due to parathyroid carcinoma: decreases serum calcium concentrations, providing symptomatic relief.

How It Works

  • Cinacalcet is an allosteric activator of the calcium‑sensing receptor (CaSR) on parathyroid cells. By increasing the sensitivity of CaSR to extracellular calcium, it suppresses parathyroid hormone (PTH) release, which in turn lowers serum calcium and phosphate concentrations. The drug’s effect is mediated through intracellular signaling pathways that inhibit PTH gene transcription and secretion.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Vomiting: occasional episodes.
  • Diarrhea: loose stools.
  • Hypocalcemia: low blood calcium levels causing tingling.
  • Muscle cramps: involuntary tightening of muscles.
  • Headache: mild to moderate pain.

Serious or Rare Side Effects

  • Severe hypocalcemia: may lead to seizures or cardiac arrhythmias.
  • Arrhythmias: irregular heart rhythms.
  • Seizures: convulsive episodes.
  • Allergic reactions: rash, itching, swelling.
  • Pancreatitis: inflammation of the pancreas.
  • Liver enzyme elevation: abnormal liver function tests.

Precautions & Warnings

Mimpara requires careful monitoring and patient education before use.

  • Monitor calcium levels: check serum calcium regularly to avoid hypocalcemia.
  • Assess PTH: periodic measurement of parathyroid hormone is recommended.
  • Adjust dose in renal impairment: consider renal function when dosing.
  • Caution in pregnancy: safety not established; use only if benefit outweighs risk.
  • Avoid in severe hypocalcemia: do not initiate therapy when calcium is critically low.
  • Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Cinacalcet may interact with several medications that affect its metabolism or calcium balance.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase cinacalcet exposure.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
  • Calcium supplements taken in high doses: can blunt the drug’s effect on serum calcium.

Moderate Interactions (Monitor Closely)

  • CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise cinacalcet levels.
  • Vitamin D analogs (e.g., calcitriol): may require dose adjustment to maintain calcium balance.
  • Loop diuretics: can enhance calcium loss, necessitating closer monitoring.

Frequently Asked Questions

Mimpara (cinacalcet) is prescribed for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis, and for hypercalcemia caused by parathyroid carcinoma. In both cases the drug helps lower elevated parathyroid hormone and serum calcium levels.

Cinacalcet acts as an allosteric activator of the calcium‑sensing receptor on parathyroid cells. By increasing the receptor’s sensitivity to extracellular calcium, it suppresses the release of parathyroid hormone, which reduces serum calcium and phosphate concentrations.

The dose of Mimpara is individualized by the prescribing clinician based on the patient’s laboratory values, renal function, and therapeutic response. Physicians start with a recommended initial dose and may titrate up or down according to calcium and PTH monitoring.

Safety of cinacalcet in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Mimpara, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mimpara belongs to the calcimimetic class, which directly targets the calcium‑sensing receptor, unlike vitamin D analogues that act downstream. It can be used alone or in combination with phosphate binders and vitamin D therapy, offering a distinct mechanism that may reduce the need for surgical parathyroidectomy.

Mimpara should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct light. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Mimpara is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed.

The most serious risks include severe hypocalcemia, which can lead to seizures, cardiac arrhythmias, or muscle spasms, and rare allergic reactions. Patients should be monitored regularly for calcium levels and signs of adverse reactions, and any severe symptoms should prompt immediate medical attention.

Mimpara is contraindicated in patients with known hypersensitivity to cinacalcet or any of its excipients, and it should not be initiated in individuals with severe, uncontrolled hypocalcemia. Clinicians must also evaluate suitability in patients with significant liver disease or those taking interacting medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cinacalcet

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT